IS:CADILAHC Cadila Healthcare Limited

Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients and wellness products, as well as animal health and veterinary, and human formulations. The company offers products in the therapeutic areas of cardiovascular, gastro intestinal, respiratory, gynecology, pain management, dermatology, anti-infective, women's healthcare, and others. It also provides consumer wellness products, such as Sugar Free, a low calorie sugar substitute; EverYuth, a range of skincare products; and Nutralite, a cholesterol free table spread. In addition, the company is developing 18 biosimilars and 7 novel products; and new drugs in cardio-metabolic disorder, inflammation, pain, and oncology therapeutic areas. Further, it is developing vaccines that are designed to address infectious diseases, including next-generation influenza, measles-mumps-rubella-varicella, typhoid, DPT-HiB, hepatitis-B, hepatitis-A, hepatitis-E, Japanese encephalitis, HPV, and combination vaccines. Additionally, the company engages in retail pharmacy, and manpower supply and administration activities. Cadila Healthcare Limited was founded in 1952 and is based in Ahmedabad, India.

395.65 INR
As of 01/25/2022

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Health Care
Industry:  Drug Manufacturers-Specialty &
Index country:  India
Country of incorporation:  India
IPO date:  07/01/2002
Stock exchange:    National Stock Exchange O
Exchange country:   India
Market cap:   405,042,724,864 INR
Current dividend yield:   0.88%
Sedol:      BYM8TG8

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy